Invitris vs Sensible Biotechnologies

<p>Invitris is a cutting-edge biotechnology platform specializing in cell-free protein synthesis. It enables you to design, express, and scale complex proteins faster and with greater flexibility than traditional cell-based methods. With systems optimized for microbial and mammalian protein production, Invitris supports rapid workflows and high-throughput screening, letting you accelerate research and development in biopharmaceuticals, industrial biotechnology, agriculture, and antimicrobial resistance.</p> <p>It provides tools for rapid protein engineering, integrating computational design with high-throughput screening, and supports seamless scalability from picoliter reactions to large-scale manufacturing. Invitris also offers co-development and licensing partnerships to help you bring innovative biotech solutions to market efficiently. The platform is designed to streamline your protein production process with scalable, tunable, and efficient technologies tailored to a variety of life science applications.</p>

<p>Sensible Biotechnologies provides a unique cell-based mRNA design and manufacturing platform aimed at overcoming the limitations of synthetic mRNA. This platform empowers you to develop pure, low immunogenicity mRNA, enabling a new era in design-based biology and therapeutic innovation. It targets researchers and developers in the biotechnology and pharmaceutical sectors seeking advanced tools for mRNA therapeutics.</p> <p>With Sensible Biotechnologies, you can leverage computational engines and cell-based methodologies to design and produce effective mRNA therapeutics. The platform is supported by partnerships with leading biotech firms like NVIDIA and Sartorius Stedim Biotech, highlighting its cutting-edge approach and scalability, helping you in your mRNA drug development journey.</p>